西替利嗪片联合氮卓斯汀鼻喷剂治疗过敏性鼻炎的疗效分析(1)
[摘要] 目的 探讨西替利嗪片、氮卓斯汀鼻喷剂联合应用于过敏性鼻炎中的治疗效果。方法 选取2014年3月～2016年3月我院收治的过敏性鼻炎患者70例，分为研究组35例和对照组35例，对照组采用常规治疗，研究组予西替利嗪片、氮卓斯汀鼻喷剂联合治疗，对比分析两组的临床治疗总有效率、满意度、不良反应及患者出现喷嚏、鼻痒、流鼻涕情况。结果 研究组患者的临床治疗总有效率、满意度、不良反应发生率及患者出现喷嚏、鼻痒、流鼻涕情况均优于对照组，两组比较差异具有统计学意义(P<0.05)。结论 西替利嗪片、氮卓斯汀鼻喷剂联合治疗过敏性鼻炎能显著提高临床治疗效果及治疗满意度，有效减少不良反应发生率，有利于疾病尽早恢复，且提高患者的生活质量，值得临床广泛推广和应用。
[关键词] 西替利嗪片；联合；氮卓斯汀鼻喷剂；过敏性鼻炎
[中图分类号] R765.21 [文献标识码] B [文章编号] 1673-9701(2017)07-0095-04
[Abstract] Objective To study and analyze the curative effect of cetirizine tablets and azelastine nasal spray in the treatment of allergic rhinitis. Methods 70 patients with allergic rhinitis from March 2014 to March 2016 in our hospital were selected and divided into the study group 35 cases and the control group 35 cases. Among them， the control group was given conventional drug therapy，the study group was treated with cetirizine tablets combined with azelastine nasal spray. The overall efficiency of clinical treatment， satisfaction degree of clinical treatment， the incidence rate of adverse reactions after treatment and the incidences of sneezing， nasal itching and unny nose were compared and analyzed between two groups. Results The overall effective rate of clinical treatment， satisfaction degree of clinical treatment， the incidence rates of adverse reactions after treatment and the incidence of sneezing， nasal itching and runny nose were better than those in the control group，there were significant differences between the two groups(P<0.05). Conclusion The combined treatment of cetirizine tablets and azelastine nasal spray in the patients with allergic rhinitis can significantly improve the clinical therapeutic effect and improve the clinical treatment satisfaction， and effectively reduce the incidence rate of adverse reactions， which helps patients to recover soon， improve the quality of life， and is worthy of wide popularization and application clinically.
[Key words] Cetirizine tablets； Combined； Azelastine nasal spray； Allergic rhinitis
过敏性鼻炎(Allergic Rhinitis，AR)是由IgE介导的鼻黏膜I型变态反应，AR在世界范围内的发病率高达10%～25%，有超过5亿人患有AR[1]，近年来在国内外的发病率呈明显逐年上升趋势。AR是遗传与环境因素共同作用的疾病，主要观点认为AR是一种IgE介导的特异性I型超敏反应，是机体Th1和Th2免疫反应失衡而表现在鼻腔黏膜上的I型变态反应，患者鼻黏膜的反应性增高，表现在临床上为经常出现鼻痒、打喷嚏或鼻塞等症状[2]。这种变态反应是由于患者鼻部出现相对较多的炎性细胞导致的，近年来，我国AR发病率逐年增长，由于AR的临床病理过程相对比较长，且该病具有反复发作的特点，故严重影响患者的日常生活质量[3]。有研究显示，西替利嗪片和氮卓斯汀鼻喷剂联合使用对治疗AR有良好效果。在有效改善患者生活质量同时，显著提高患者治疗满意度。所以，本文将对西替利嗪片、氮卓斯汀鼻喷剂联合应用于AR患者的疗效进行研究、分析。现报道如下。
1 资料与方法
1.1一般资料
选取我院于2014年3月～2016年3月收治的AR患者70例，分为研究组35例和对照组35例，其中，对照组行常规治疗，研究組予西替利嗪片、氮卓斯汀鼻喷剂联合治疗。其中，研究组男19例，女16例，最大年龄73岁，最小年龄18岁，平均年龄41岁。对照组男17例，女18例，最大年龄70岁，最小年龄19岁，平均年龄40岁，两组患者的基础资料比较，差异无统计学意义。本研究履行赫尔辛基宣言相一致原则并获得台州市中心医院伦理委员会认可，患者均已经获知情同意并签署知情同意书。, 百拇医药(许航宇 舒海荣 宋建新)
[关键词] 西替利嗪片；联合；氮卓斯汀鼻喷剂；过敏性鼻炎
[中图分类号] R765.21 [文献标识码] B [文章编号] 1673-9701(2017)07-0095-04
[Abstract] Objective To study and analyze the curative effect of cetirizine tablets and azelastine nasal spray in the treatment of allergic rhinitis. Methods 70 patients with allergic rhinitis from March 2014 to March 2016 in our hospital were selected and divided into the study group 35 cases and the control group 35 cases. Among them， the control group was given conventional drug therapy，the study group was treated with cetirizine tablets combined with azelastine nasal spray. The overall efficiency of clinical treatment， satisfaction degree of clinical treatment， the incidence rate of adverse reactions after treatment and the incidences of sneezing， nasal itching and unny nose were compared and analyzed between two groups. Results The overall effective rate of clinical treatment， satisfaction degree of clinical treatment， the incidence rates of adverse reactions after treatment and the incidence of sneezing， nasal itching and runny nose were better than those in the control group，there were significant differences between the two groups(P<0.05). Conclusion The combined treatment of cetirizine tablets and azelastine nasal spray in the patients with allergic rhinitis can significantly improve the clinical therapeutic effect and improve the clinical treatment satisfaction， and effectively reduce the incidence rate of adverse reactions， which helps patients to recover soon， improve the quality of life， and is worthy of wide popularization and application clinically.
[Key words] Cetirizine tablets； Combined； Azelastine nasal spray； Allergic rhinitis
过敏性鼻炎(Allergic Rhinitis，AR)是由IgE介导的鼻黏膜I型变态反应，AR在世界范围内的发病率高达10%～25%，有超过5亿人患有AR[1]，近年来在国内外的发病率呈明显逐年上升趋势。AR是遗传与环境因素共同作用的疾病，主要观点认为AR是一种IgE介导的特异性I型超敏反应，是机体Th1和Th2免疫反应失衡而表现在鼻腔黏膜上的I型变态反应，患者鼻黏膜的反应性增高，表现在临床上为经常出现鼻痒、打喷嚏或鼻塞等症状[2]。这种变态反应是由于患者鼻部出现相对较多的炎性细胞导致的，近年来，我国AR发病率逐年增长，由于AR的临床病理过程相对比较长，且该病具有反复发作的特点，故严重影响患者的日常生活质量[3]。有研究显示，西替利嗪片和氮卓斯汀鼻喷剂联合使用对治疗AR有良好效果。在有效改善患者生活质量同时，显著提高患者治疗满意度。所以，本文将对西替利嗪片、氮卓斯汀鼻喷剂联合应用于AR患者的疗效进行研究、分析。现报道如下。
1 资料与方法
1.1一般资料
选取我院于2014年3月～2016年3月收治的AR患者70例，分为研究组35例和对照组35例，其中，对照组行常规治疗，研究組予西替利嗪片、氮卓斯汀鼻喷剂联合治疗。其中，研究组男19例，女16例，最大年龄73岁，最小年龄18岁，平均年龄41岁。对照组男17例，女18例，最大年龄70岁，最小年龄19岁，平均年龄40岁，两组患者的基础资料比较，差异无统计学意义。本研究履行赫尔辛基宣言相一致原则并获得台州市中心医院伦理委员会认可，患者均已经获知情同意并签署知情同意书。, 百拇医药(许航宇 舒海荣 宋建新)